CN111298190A - Hemostatic material for infants and preparation method thereof - Google Patents
Hemostatic material for infants and preparation method thereof Download PDFInfo
- Publication number
- CN111298190A CN111298190A CN202010183178.XA CN202010183178A CN111298190A CN 111298190 A CN111298190 A CN 111298190A CN 202010183178 A CN202010183178 A CN 202010183178A CN 111298190 A CN111298190 A CN 111298190A
- Authority
- CN
- China
- Prior art keywords
- infants
- hemostatic material
- parts
- glucopyranoside
- allyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000002439 hemostatic effect Effects 0.000 title claims abstract description 78
- 239000000463 material Substances 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims description 37
- 108010039918 Polylysine Proteins 0.000 claims abstract description 44
- 229920000656 polylysine Polymers 0.000 claims abstract description 44
- NCAVPEPBIJTYSO-UHFFFAOYSA-N 4-hydroxybutyl prop-2-enoate;2-(oxiran-2-ylmethoxymethyl)oxirane Chemical compound C1OC1COCC1CO1.OCCCCOC(=O)C=C NCAVPEPBIJTYSO-UHFFFAOYSA-N 0.000 claims abstract description 39
- -1 allyl B-D glucopyranoside modified graphene quantum dots Chemical class 0.000 claims abstract description 32
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 15
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 15
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 15
- 229960004853 betadex Drugs 0.000 claims abstract description 15
- 239000012621 metal-organic framework Substances 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- BGXGWGOYUVADDG-UHFFFAOYSA-N 4-(but-2-enoylamino)-2-hydroxybenzoic acid Chemical compound CC=CC(=O)NC1=CC=C(C(O)=O)C(O)=C1 BGXGWGOYUVADDG-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000007822 coupling agent Substances 0.000 claims abstract description 7
- 239000003999 initiator Substances 0.000 claims abstract description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 63
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 29
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- XJNKZTHFPGIJNS-SYHAXYEDSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-prop-2-enoxyoxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OCC=C)[C@H](O)[C@@H](O)[C@@H]1O XJNKZTHFPGIJNS-SYHAXYEDSA-N 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 239000006087 Silane Coupling Agent Substances 0.000 claims description 13
- 238000002390 rotary evaporation Methods 0.000 claims description 12
- 238000001125 extrusion Methods 0.000 claims description 10
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 8
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 239000002096 quantum dot Substances 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 239000012298 atmosphere Substances 0.000 claims description 4
- 239000011261 inert gas Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000001307 helium Substances 0.000 claims description 3
- 229910052734 helium Inorganic materials 0.000 claims description 3
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 3
- 229910052754 neon Inorganic materials 0.000 claims description 3
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 229910052786 argon Inorganic materials 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000023597 hemostasis Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- JYLCVRHQTJPCTN-UHFFFAOYSA-N 2-hydroxy-4-(2-methylprop-2-enoylamino)benzoic acid Chemical compound CC(=C)C(=O)NC1=CC=C(C(O)=O)C(O)=C1 JYLCVRHQTJPCTN-UHFFFAOYSA-N 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 239000004368 Modified starch Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000019426 modified starch Nutrition 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108010027529 Bio-glue Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a hemostatic material for infants, which is characterized by being prepared from the following raw materials, by weight, 5-10 parts of sodium- β -cyclodextrin metal organic framework, 50-60 parts of 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine, 1-2 parts of allyl B-D glucopyranoside modified graphene quantum dots, 8-12 parts of incense ash, 1-3 parts of 4-methylacrylamidosalicylic acid, 0.5-1.5 parts of coupling agent and 0.05-0.08 part of initiator.
Description
Technical Field
The invention relates to the technical field of hemostatic materials, in particular to a hemostatic material for infants and a preparation method thereof.
Background
The skin of infants and young children differs significantly from the skin of adults in structure, function and composition. The skin structure and the function of the infant skin care product are in a continuously growing and perfect state, and the infant skin care product is relatively delicate and fragile, and is very easy to cause wound bleeding of infants if the infants carelessly fall down, collide with the infant skin care product and seriously burn and scald in daily life. Blood is one of basic substances constituting a human body and maintaining human life activities, has effects of nourishing tissues, regulating organ activities and defending against harmful substances, and if excessive bleeding occurs in a human body, shock is caused, and more serious people cause life risks, and bleeding is accompanied by pain, inflammation and the like. Therefore, the need for a hemostatic material suitable for infants is important to ensure the life safety of infants who do not have self-care ability and self-protection ability and cannot express their physical states in language.
With the rapid development of science and technology, hemostatic materials have been developed. At present, the common hemostatic materials in domestic market mainly comprise fibrin glue, gelatin sponge, collagen, chitosan and the like. However, fibrin glue has good adhesiveness, but cannot be applied alone to hemostasis of large wounds because of its inability to compress hemostasis, and is also susceptible to allergy and viral infection because it is derived from blood of animals and humans; the porous structure of the gelatin sponge has strong absorption effect on blood, activates platelets and promotes thrombosis, but the gelatin sponge has poor adhesion to the internal wound part and poor degradation and absorption in vivo, thereby greatly increasing the risk of infection of the wound part; although chitosan has certain bacteriostatic and hemostatic effects, the hemostatic effect is limited, so the chitosan is not ideal for the hemostasis of the parts with large bleeding. Other hemostatic materials in the prior art such as zeolite and oxidized regenerated cellulose are easy to cause tissue necrosis, and cyanoacrylate, glutaraldehyde-albumin Bioglue and cellulose ether are easy to cause local adhesion.
Chinese patent document CN108619556A discloses a preparation method of porous fiber composite hemostatic material, which mainly comprises modified zeolite and modified starch loaded on the modified zeolite, wherein the modified starch is prepared by pre-gelatinizing raw starch, then performing deformation treatment, and finally performing agglomeration, pelleting and screening.
The patent of application No. 201410097478.0 discloses a preparation method of an absorbable and degradable starch hemostatic material, which is characterized in that starch is inactivated, virus-removed and modified to prepare modified starch, and then the modified starch is combined with other biological materials to prepare membrane products or sponge products.
Therefore, the development of the infant hemostatic material with remarkable hemostatic effect, high hemostatic efficiency, small irritation to infant tissues, high safety and small toxic and side effects is very important.
Disclosure of Invention
In view of the above, the invention aims to provide a hemostatic material for infants and a preparation method thereof, wherein the preparation method has simple process and low production cost, and can be widely used for continuous hemostasis of internal and external wounds of infants; the hemostatic material for the infants prepared by the preparation method has the advantages of obvious hemostatic effect, high hemostatic efficiency, small irritation to infant tissues, high safety, small toxic and side effects and higher clinical practical value.
In order to achieve the purpose, the invention adopts the technical scheme that:
the hemostatic material for infants is characterized by being prepared from the following raw materials, by weight, 5-10 parts of sodium- β -cyclodextrin metal organic framework, 50-60 parts of 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine, 1-2 parts of allyl B-D glucopyranoside modified graphene quantum dots, 8-12 parts of incense ash, 1-3 parts of 4-methylacrylamido salicylic acid, 0.5-1.5 parts of a coupling agent and 0.05-0.08 part of an initiator.
Preferably, the initiator is at least one of azobisisobutyronitrile and azobisisoheptonitrile.
Preferably, the coupling agent is at least one of a silane coupling agent KH550, a silane coupling agent KH560 and a silane coupling agent KH 570.
Further, the preparation method of the allyl B-D glucopyranoside modified graphene quantum dot comprises the following steps: dispersing graphene quantum dots in an organic solvent, adding allyl B-D glucopyranoside, 4-dimethylaminopyridine and 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride into the organic solvent, stirring the mixture at the temperature of 30-50 ℃ under the atmosphere of nitrogen or inert gas for reaction for 5-7 hours, centrifuging the mixture, washing the mixture by using ethanol for 2-4 times, and rotationally evaporating the ethanol to remove the ethanol to obtain the allyl B-D glucopyranoside modified graphene quantum dots.
Preferably, the mass ratio of the graphene quantum dots to the organic solvent to the allyl B-D glucopyranoside to the 4-dimethylaminopyridine to the 1-ethyl- (3-dimethylaminopropyl) carbonyldiimine hydrochloride is (3-5) to (10-20) to 1 (0.6-0.8) to 0.35; the organic solvent is any one of tetrahydrofuran, dichloromethane and ethyl acetate; the inert gas is any one of helium, neon and argon.
Further, the preparation method of the 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine comprises the following steps: adding 4-hydroxybutyl acrylate glycidyl ether and hyperbranched polylysine into tetrahydrofuran, adding triethylamine, stirring and reacting at 25-40 ℃ for 6-8 hours, and then performing rotary evaporation to remove tetrahydrofuran and triethylamine, thereby obtaining the 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine.
Preferably, the molar ratio of the 4-hydroxybutyl acrylate glycidyl ether to the hyperbranched polylysine to the tetrahydrofuran to the triethylamine is (2-3) to 1 (10-20) to (0.8-1.2).
Preferably, the hyperbranched polylysine is hyperbranched polylysine G4, and the preparation method is as follows: chinese patent application No. 201910264905.2, example 1.
Preferably, the preparation method of the sodium- β -cyclodextrin metal-organic framework is shown in the Chinese patent application No. 201510173782.3.
Another object of the present invention is to provide a method for preparing the hemostatic material for infants, which comprises the steps of: the raw materials are uniformly mixed according to a proportion to obtain a mixed material, then the mixed material is added into a double-screw extruder for extrusion molding, and after cooling to room temperature and sterilization, the hemostatic material for infants is obtained.
Preferably, the extrusion molding temperature is: the first zone 170-.
Adopt the produced beneficial effect of above-mentioned technical scheme to lie in:
(1) the preparation method of the hemostatic material for infants provided by the invention is simple in process and low in production cost, and can be widely used for continuous hemostasis of internal and external wounds of infants.
(2) The hemostatic material for infants overcomes the defects of easy allergy and virus infection, poor adhesion to visceral wound parts, poor degradation and absorption in vivo, limited hemostatic effect, easy tissue necrosis and easy local adhesion of the hemostatic materials on the market, and has the advantages of obvious hemostatic effect, high hemostatic efficiency, small irritation to infant tissues, high safety, small toxic and side effects and high clinical practical value.
(3) According to the hemostatic material for infants, acrylamide and acrylate structures are respectively introduced to the molecular chains of 4-methacrylamide salicylic acid and 4-hydroxybutylacrylate glycidyl ether modified hyperbranched polylysine, so that the formed material has a strong adhesion effect, can fill tissue defect parts, stimulate granulation tissue growth, and promote recovery and healing of skin injury parts of infants; 4-hydroxy butyl acrylate glycidyl ether modified hyperbranched polylysine has amino terminal groups, so that the amino terminal groups are positively charged, and molecules of the amino terminal groups can directly connect red blood cells on wound surfaces together to promote blood coagulation, thereby achieving the effect of stopping bleeding; the hemostatic material adopts a branched structure and polylysine as a matrix, so that the hemostatic material has good biocompatibility and small irritation to skin; in addition, it also has the effect of inhibiting the growth of various bacteria and fungi; carboxyl is introduced by 4-methylacrylamidosilic acid, and the carboxyl can be complexed with iron ions in red blood cells to form blood clots to block blood vessels, so that the hemostatic effect is further improved.
(4) The invention provides a hemostatic material for infants, which is added with a sodium- β -cyclodextrin metal organic framework, allyl B-D glucopyranoside modified graphene quantum dots and incense for synergistic action, can quickly absorb water in blood, and concentrates platelets and blood coagulation factors through non-chemical reaction so as to effectively stop bleeding, wherein the introduced sodium- β -cyclodextrin metal organic framework has a specific cavity structure, can be synergistically acted with other raw materials to effectively improve adsorption capacity and has good biological compatibility, the introduction of the graphene quantum dots can enhance liquid absorption capacity and stimulation capacity of blood cell interfaces, and can stimulate erythrocytes and platelets to change regular forms and structures on the interfaces besides quickly absorbing plasma, so that the biological functionality of cells is influenced to a great extent, and thus blood coagulation is promoted, and in addition, the hemostatic material also has the effects of resisting bacteria and releasing far infrared rays, and can provide a favorable environment for wound healing.
(5) According to the hemostatic material for infants, the sodium- β -cyclodextrin metal organic framework is easily included with 4-methylacrylamidosalicylic acid, vinyl-containing substances such as 4-methylacrylamidosalicylic acid, 4-hydroxybutylacrylate glycidyl ether modified hyperbranched polylysine and allyl B-D glucopyranoside modified graphene quantum dots are subjected to free radical polymerization in the material forming stage to form a three-dimensional network structure, so that the comprehensive performance of the hemostatic material is effectively improved, the performance stability is greatly improved, in addition, the added raw materials are good in biocompatibility, and safe and environment-friendly in use.
Detailed Description
In order to make the technical solutions of the present invention better understood and make the above features, objects, and advantages of the present invention more comprehensible, the present invention is further described with reference to the following examples. The examples are intended to illustrate the invention only and are not intended to limit the scope of the invention.
The raw materials of the embodiment of the invention are all purchased commercially, the hyperbranched polylysine is hyperbranched polylysine G4, the preparation method is shown in the embodiment 1 of the Chinese patent with the application number of 201910264905.2, and the preparation method of the sodium- β -cyclodextrin metal-organic framework is shown in the embodiment of the Chinese patent with the application number of 201510173782.3.
Example 1
The hemostatic material for infants is characterized by being prepared from the following raw materials, by weight, 5 parts of sodium- β -cyclodextrin metal organic framework, 50 parts of 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine, 1 part of allyl B-D glucopyranoside modified graphene quantum dots, 8 parts of incense ash, 1 part of 4-methylacrylamido salicylic acid, KH5500.5 parts of a silane coupling agent and 0.05 part of azobisisobutyronitrile.
The preparation method of the allyl B-D glucopyranoside modified graphene quantum dot comprises the following steps: dispersing graphene quantum dots in tetrahydrofuran, adding allyl B-D glucopyranoside, 4-dimethylaminopyridine and 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride into the tetrahydrofuran, stirring the mixture at 30 ℃ under a nitrogen atmosphere to react for 5 hours, centrifuging the mixture, washing the mixture with ethanol and centrifuging the mixture for 2 times, and performing rotary evaporation to remove the ethanol to obtain the allyl B-D glucopyranoside modified graphene quantum dots; the mass ratio of the graphene quantum dots to tetrahydrofuran to allyl B-D glucopyranoside to 4-dimethylaminopyridine to 1-ethyl- (3-dimethylaminopropyl) carbonyldiimine hydrochloride to 0.6 to 0.35 is 3:10:1: 0.6.
The preparation method of the 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine comprises the following steps: adding 4-hydroxybutyl acrylate glycidyl ether and hyperbranched polylysine into tetrahydrofuran, adding triethylamine, stirring and reacting at 25 ℃ for 6 hours, and then performing rotary evaporation to remove tetrahydrofuran and triethylamine to obtain 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine; the molar ratio of the 4-hydroxybutyl acrylate glycidyl ether to the hyperbranched polylysine to the tetrahydrofuran to the triethylamine is 2:1:10: 0.8.
The preparation method of the hemostatic material for infants is characterized by comprising the following steps: uniformly mixing the raw materials in proportion to obtain a mixed material, adding the mixed material into a double-screw extruder, extruding and molding, cooling to room temperature, and sterilizing to obtain the hemostatic material for infants; the extrusion molding temperature is as follows: the first zone 170 deg.C, the second zone 182 deg.C, the third zone 193 deg.C, the fourth zone 205 deg.C, the fifth zone 215 deg.C, and the die temperature 220 deg.C.
Example 2
The hemostatic material for infants is characterized by being prepared from 6 parts by weight of sodium- β -cyclodextrin metal organic framework, 53 parts by weight of 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine, 1.2 parts by weight of allyl B-D glucopyranoside modified graphene quantum dots, 9 parts by weight of incense ash, 1.5 parts by weight of 4-methylacrylamidosalicylic acid, KH5600.7 parts by weight of a silane coupling agent and 0.06 parts by weight of azodiisoheptonitrile.
The preparation method of the allyl B-D glucopyranoside modified graphene quantum dot comprises the following steps: dispersing graphene quantum dots in dichloromethane, adding allyl B-D glucopyranoside, 4-dimethylaminopyridine and 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride into the dichloromethane, stirring the mixture at 35 ℃ under a helium atmosphere to react for 5.5 hours, centrifuging the mixture, washing the mixture with ethanol and centrifuging the mixture for 3 times, and performing rotary evaporation to remove the ethanol to obtain the allyl B-D glucopyranoside modified graphene quantum dots; the mass ratio of the graphene quantum dots to the dichloromethane to the allyl B-D glucopyranoside to the 4-dimethylaminopyridine to the 1-ethyl- (3-dimethylaminopropyl) carbonyldiimine hydrochloride is 3.5:12:1:0.65: 0.35.
The preparation method of the 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine comprises the following steps: adding 4-hydroxybutyl acrylate glycidyl ether and hyperbranched polylysine into tetrahydrofuran, adding triethylamine, stirring and reacting at 30 ℃ for 6.5 hours, and then performing rotary evaporation to remove tetrahydrofuran and triethylamine, thereby obtaining 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine; the molar ratio of the 4-hydroxybutyl acrylate glycidyl ether to the hyperbranched polylysine to the tetrahydrofuran to the triethylamine is 2.3:1:12: 0.9.
The preparation method of the hemostatic material for infants is characterized by comprising the following steps: uniformly mixing the raw materials in proportion to obtain a mixed material, adding the mixed material into a double-screw extruder, extruding and molding, cooling to room temperature, and sterilizing to obtain the hemostatic material for infants; the extrusion molding temperature is as follows: the first zone 173 ℃, the second zone 185 ℃, the third zone 195 ℃, the fourth zone 207 ℃, the fifth zone 217 ℃ and the die temperature is 223 ℃.
Example 3
The hemostatic material for infants is characterized by being prepared from 8 parts by weight of sodium- β -cyclodextrin metal organic framework, 55 parts by weight of 4-hydroxybutylacrylate glycidyl ether modified hyperbranched polylysine, 1.5 parts by weight of allyl B-D glucopyranoside modified graphene quantum dots, 10 parts by weight of incense ash, 2 parts by weight of 4-methacrylamido salicylic acid, a silane coupling agent KH5701 and 0.065 parts by weight of azobisisobutyronitrile.
The preparation method of the allyl B-D glucopyranoside modified graphene quantum dot comprises the following steps: dispersing graphene quantum dots in ethyl acetate, adding allyl B-D glucopyranoside, 4-dimethylaminopyridine and 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride into the ethyl acetate, stirring the mixture at 40 ℃ under the atmosphere of neon for reacting for 6 hours, centrifuging the mixture, washing the mixture with ethanol for 3 times, and performing rotary evaporation to remove the ethanol to obtain the allyl B-D glucopyranoside modified graphene quantum dots; the mass ratio of the graphene quantum dots to the ethyl acetate to the allyl B-D glucopyranoside to the 4-dimethylaminopyridine to the 1-ethyl- (3-dimethylaminopropyl) carbonyldiimine hydrochloride is 4:15:1:0.7: 0.35.
The preparation method of the 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine comprises the following steps: adding 4-hydroxybutyl acrylate glycidyl ether and hyperbranched polylysine into tetrahydrofuran, adding triethylamine, stirring and reacting at 33 ℃ for 7 hours, and then performing rotary evaporation to remove tetrahydrofuran and triethylamine to obtain 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine; the molar ratio of the 4-hydroxybutyl acrylate glycidyl ether to the hyperbranched polylysine to the tetrahydrofuran to the triethylamine is 2.5:1:15: 1.
The preparation method of the hemostatic material for infants is characterized by comprising the following steps: the raw materials are uniformly mixed according to a proportion to obtain a mixed material, then the mixed material is added into a double-screw extruder for extrusion molding, and after cooling to room temperature and sterilization, the hemostatic material for infants is obtained. Preferably, the extrusion molding temperature is: the first zone was 175 deg.C, the second zone was 186 deg.C, the third zone was 197 deg.C, the fourth zone was 207 deg.C, the fifth zone was 217 deg.C, and the die temperature was 225 deg.C.
Example 4
The hemostatic material for infants is characterized by being prepared from 9 parts by weight of sodium- β -cyclodextrin metal organic framework, 58 parts by weight of 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine, 1.8 parts by weight of allyl B-D glucopyranoside modified graphene quantum dots, 11 parts by weight of incense ash, 2.5 parts by weight of 4-methacrylamido salicylic acid, 1.4 parts by weight of coupling agent and 0.07 part by weight of initiator.
The initiator is formed by mixing azodiisobutyronitrile and azodiisoheptonitrile according to the mass ratio of 3: 5; the coupling agent is formed by mixing a silane coupling agent KH550, a silane coupling agent KH560 and a silane coupling agent KH570 according to the mass ratio of 1:3: 5.
The preparation method of the allyl B-D glucopyranoside modified graphene quantum dot comprises the following steps: dispersing graphene quantum dots in tetrahydrofuran, adding allyl B-D glucopyranoside, 4-dimethylaminopyridine and 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride into the tetrahydrofuran, stirring and reacting for 6.5 hours at 48 ℃ under an argon atmosphere, centrifuging, washing and centrifuging for 4 times by using ethanol, and performing rotary evaporation to remove the ethanol to obtain the allyl B-D glucopyranoside modified graphene quantum dots; the mass ratio of the graphene quantum dots to tetrahydrofuran to allyl B-D glucopyranoside to 4-dimethylaminopyridine to 1-ethyl- (3-dimethylaminopropyl) carbonyldiimine hydrochloride to 0.75 to 0.35 is 4.7:18:1: 0.75.
The preparation method of the 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine comprises the following steps: adding 4-hydroxybutyl acrylate glycidyl ether and hyperbranched polylysine into tetrahydrofuran, adding triethylamine, stirring and reacting at 38 ℃ for 7.8 hours, and then performing rotary evaporation to remove tetrahydrofuran and triethylamine, thereby obtaining 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine; the molar ratio of the 4-hydroxybutyl acrylate glycidyl ether to the hyperbranched polylysine to the tetrahydrofuran to the triethylamine is 2.8:1:18: 1.1.
The preparation method of the hemostatic material for infants is characterized by comprising the following steps: uniformly mixing the raw materials in proportion to obtain a mixed material, adding the mixed material into a double-screw extruder, extruding and molding, cooling to room temperature, and sterilizing to obtain the hemostatic material for infants; the extrusion molding temperature is as follows: the first zone 178 deg.C, the second zone 189 deg.C, the third zone 197 deg.C, the fourth zone 209 deg.C, the fifth zone 218 deg.C, and the die temperature 228 deg.C.
Example 5
The hemostatic material for infants is characterized by being prepared from the following raw materials, by weight, 10 parts of sodium- β -cyclodextrin metal organic framework, 60 parts of 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine, 2 parts of allyl B-D glucopyranoside modified graphene quantum dots, 12 parts of incense ash, 3 parts of 4-methylacrylamido salicylic acid, KH5601.5 parts of a silane coupling agent and 0.08 part of azobisisoheptonitrile.
The preparation method of the allyl B-D glucopyranoside modified graphene quantum dot comprises the following steps: dispersing graphene quantum dots in ethyl acetate, adding allyl B-D glucopyranoside, 4-dimethylaminopyridine and 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride into the ethyl acetate, stirring the mixture at 50 ℃ under the nitrogen atmosphere to react for 7 hours, centrifuging the mixture, washing the mixture with ethanol and centrifuging the mixture for 4 times, and performing rotary evaporation to remove the ethanol to obtain the allyl B-D glucopyranoside modified graphene quantum dots; the mass ratio of the graphene quantum dots to the ethyl acetate to the allyl B-D glucopyranoside to the 4-dimethylaminopyridine to the 1-ethyl- (3-dimethylaminopropyl) carbonyldiimine hydrochloride is 5:20:1:0.8: 0.35.
The preparation method of the 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine comprises the following steps: adding 4-hydroxybutyl acrylate glycidyl ether and hyperbranched polylysine into tetrahydrofuran, adding triethylamine, stirring and reacting for 8 hours at 40 ℃, and then performing rotary evaporation to remove tetrahydrofuran and triethylamine to obtain 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine; the molar ratio of the 4-hydroxybutyl acrylate glycidyl ether to the hyperbranched polylysine to the tetrahydrofuran to the triethylamine is 3:1:20: 1.2.
The preparation method of the hemostatic material for infants is characterized by comprising the following steps: uniformly mixing the raw materials in proportion to obtain a mixed material, adding the mixed material into a double-screw extruder, extruding and molding, cooling to room temperature, and sterilizing to obtain the hemostatic material for infants; the extrusion molding temperature is as follows: the first zone was 180 ℃, the second zone was 190 ℃, the third zone was 200 ℃, the fourth zone was 210 ℃, the fifth zone was 220 ℃ and the die temperature was 230 ℃.
Comparative example 1
This example provides a hemostatic material for infants, which has a formulation and a preparation method substantially the same as those of example 1, except that sodium- β -cyclodextrin metal-organic framework is not added.
Comparative example 2
The present example provides a hemostatic material for infants, which has a formulation and a preparation method substantially the same as those of example 1, except that allyl B-D glucopyranoside-modified graphene quantum dots are not added.
Comparative example 3
This example provides a hemostatic material for infants, which has a formulation and a preparation method substantially the same as those of example 1, except that 4-methacrylamidosalicylic acid is not added.
Comparative example 4
This example provides a hemostatic material, the formulation and preparation method of which are the same as those of example 1 of the chinese patent application No. 201610119595.1.
To further illustrate the beneficial technical effects of the embodiments of the present invention, the hemostatic materials described in examples 1-5 and comparative examples 1-4 were tested for performance, the test results are shown in table 1, and the test methods are as follows:
(1) hemostatic effect, biocompatibility: 45 patients of clinical internal medicine infant surgery are selected and randomly divided into groups of examples 1-5 and groups of comparative examples 1-4, 5 patients in each group are laid and used with 1.5cm multiplied by 1.5cm of hemostatic materials prepared in the examples 1-4 and the comparative examples 1-5 respectively in the surgical process, wound surfaces of the same 1.0cm multiplied by 0.2cm are selected for testing hemostatic performance, hemostatic effect and biocompatibility are observed, a stopwatch is used for timing, hemostatic effect is observed, hemostatic time is recorded after complete hemostasis is achieved, and then average hemostatic time of each group of testers is taken.
(2) Tensile property: the test is carried out by referring to the GB/T1040.1-2006 test method.
TABLE 1
| Item | Time of hemostasis | Biocompatibility | Tensile strength |
| Unit of | s | Is divided into | MPa |
| Example 1 | 30 | Without rejection | 11.8 |
| Example 2 | 27 | Without rejection | 12.3 |
| Example 3 | 23 | Without rejection | 12.5 |
| Example 4 | 20 | Without rejection | 12.8 |
| Example 5 | 17 | Without rejection | 13.0 |
| Comparative example 1 | 40 | Without rejection | 11.0 |
| Comparative example 2 | 42 | Without rejection | 10.3 |
| Comparative example 3 | 38 | Without rejection | 10.5 |
| Comparative example 4 | 52 | Without rejection | 9.2 |
As can be seen from table 1, the hemostatic material for infants disclosed by the invention has more excellent hemostatic effect, biocompatibility and mechanical properties, which are the result of the synergistic effect of sodium- β -cyclodextrin metal-organic framework, allyl B-D glucopyranoside modified graphene quantum dots and 4-methacrylamidosalicylic acid.
The foregoing shows and describes the general principles and broad features of the present invention and advantages thereof. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (10)
1. The hemostatic material for infants is characterized by being prepared from the following raw materials, by weight, 5-10 parts of sodium- β -cyclodextrin metal organic framework, 50-60 parts of 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine, 1-2 parts of allyl B-D glucopyranoside modified graphene quantum dots, 8-12 parts of incense ash, 1-3 parts of 4-methylacrylamido salicylic acid, 0.5-1.5 parts of a coupling agent and 0.05-0.08 part of an initiator.
2. The hemostatic material for infants according to claim 1, wherein the initiator is at least one of azobisisobutyronitrile and azobisisoheptonitrile.
3. The hemostatic material for infants according to claim 1, wherein the coupling agent is at least one of silane coupling agent KH550, silane coupling agent KH560 and silane coupling agent KH 570.
4. The hemostatic material for infants, as claimed in claim 1, wherein the preparation method of the allyl B-D glucopyranoside modified graphene quantum dot comprises the following steps: dispersing graphene quantum dots in an organic solvent, adding allyl B-D glucopyranoside, 4-dimethylaminopyridine and 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride into the organic solvent, stirring the mixture at the temperature of 30-50 ℃ under the atmosphere of nitrogen or inert gas for reaction for 5-7 hours, centrifuging the mixture, washing the mixture by using ethanol for 2-4 times, and rotationally evaporating the ethanol to remove the ethanol to obtain the allyl B-D glucopyranoside modified graphene quantum dots.
5. The hemostatic material for infants according to claim 4, wherein the mass ratio of the graphene quantum dots, the organic solvent, the allyl B-D glucopyranoside, the 4-dimethylaminopyridine and the 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride is (3-5): 10-20):1, (0.6-0.8): 0.35.
6. The hemostatic material for infants according to claim 4, wherein the organic solvent is any one of tetrahydrofuran, dichloromethane and ethyl acetate; the inert gas is any one of helium, neon and argon.
7. The hemostatic material for infants according to claim 1, wherein the preparation method of the 4-hydroxybutylacrylate glycidyl ether modified hyperbranched polylysine comprises the following steps: adding 4-hydroxybutyl acrylate glycidyl ether and hyperbranched polylysine into tetrahydrofuran, adding triethylamine, stirring and reacting at 25-40 ℃ for 6-8 hours, and then performing rotary evaporation to remove tetrahydrofuran and triethylamine, thereby obtaining the 4-hydroxybutyl acrylate glycidyl ether modified hyperbranched polylysine.
8. The hemostatic material for infants according to claim 7, wherein the molar ratio of the 4-hydroxybutylacrylate glycidyl ether to the hyperbranched polylysine to the tetrahydrofuran to the triethylamine is (2-3) to 1 (10-20) to (0.8-1.2).
9. The hemostatic material for infants according to any one of claims 1 to 8, wherein the preparation method of the hemostatic material for infants comprises the following steps: the raw materials are uniformly mixed according to a proportion to obtain a mixed material, then the mixed material is added into a double-screw extruder for extrusion molding, and after cooling to room temperature and sterilization, the hemostatic material for infants is obtained.
10. The hemostatic material for infants, as claimed in claim 9, wherein the extrusion temperature is: the first zone 170-.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010183178.XA CN111298190A (en) | 2020-03-16 | 2020-03-16 | Hemostatic material for infants and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010183178.XA CN111298190A (en) | 2020-03-16 | 2020-03-16 | Hemostatic material for infants and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111298190A true CN111298190A (en) | 2020-06-19 |
Family
ID=71145700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010183178.XA Withdrawn CN111298190A (en) | 2020-03-16 | 2020-03-16 | Hemostatic material for infants and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111298190A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114984132A (en) * | 2022-05-30 | 2022-09-02 | 浙江大学 | Wound spray capable of promoting coagulation and repairing and preparation method thereof |
-
2020
- 2020-03-16 CN CN202010183178.XA patent/CN111298190A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114984132A (en) * | 2022-05-30 | 2022-09-02 | 浙江大学 | Wound spray capable of promoting coagulation and repairing and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lan et al. | Chitosan/gelatin composite sponge is an absorbable surgical hemostatic agent | |
| Li et al. | Preparation and the hemostatic property study of porous gelatin microspheres both in vitro and in vivo | |
| CN110152051B (en) | Water-absorbing burn wound antibacterial dressing and preparation method and application thereof | |
| US20210100830A1 (en) | Starch-based hemostatic powder and preparation method thereof | |
| Wang et al. | Rational design of porous starch/hyaluronic acid composites for hemostasis | |
| CN103349791A (en) | Novel microporous medical hemostatic material and preparation method thereof | |
| Mirzadeh et al. | Preparation of Chitosan Derived From Shrimp | |
| CN112516374B (en) | A kind of chitosan/Mxene antibacterial composite sponge for hemostasis and preparation method thereof | |
| CN103055343B (en) | Potato starch-hyaluronic acid composite hemostatic powder and preparation method thereof | |
| Zhou et al. | Preparation and application of hemostatic hydrogels | |
| CN112156222A (en) | Preparation method of hemostatic, antibacterial and healing-promoting frozen gel sponge | |
| CN102220017A (en) | Injectable moulded silk fibroin hydrogel and preparation method thereof | |
| Song et al. | Effects of degree of deacetylation on hemostatic performance of partially deacetylated chitin sponges | |
| CN111450306B (en) | External nano hydroxyapatite/polydopamine wet adhesion type styptic powder and preparation method thereof | |
| CN111298190A (en) | Hemostatic material for infants and preparation method thereof | |
| CN110755674B (en) | Hemostatic powder and preparation method thereof | |
| CN109125795B (en) | Polysaccharide hemostatic composition and preparation method and application thereof | |
| CN105233326A (en) | Preparation method and preparation of absorbable micropore vacuum polysaccharide particles | |
| CN106955370A (en) | Composite starch styptic powder | |
| CN106822984A (en) | A kind of biocompatibility is strong, preventing tissue is adhered, the degradable absorption antibacterial anti hemorrhagic composition of wound healing promoting and application thereof | |
| JP2022534860A (en) | Biocellulose fiber, hemostatic dressing containing same and related applications | |
| CN107029280B (en) | A kind of preparation method of chitosan-alginate soft capsule hemostatic material | |
| CN110947022A (en) | Preparation method of chitosan-based composite antibacterial dressing | |
| CN102167847B (en) | Chitosan and sulfating grifolan mixed gel freeze-dried sponge, and preparation method and application thereof | |
| CN102988407A (en) | Starch-hyaluronic acid hemostatic agent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200619 |